医脉通_medlive.cn

首页 > 阳光明媚的医脉通

关注TA

分享TA 发站内信

阳光明媚

详细资料

性别：女

职务：保密

单位：保密

职称：住院医师

专业：肿瘤内科

全站动态

TA关注的

TA的动态

阳光明媚翻译了文献标题：

05-21 10:59

妊娠高血压和乳腺癌风险

Background:Hypertensive diseases in pregnancy may be associated with a reduced risk of breast cancer. Most previous studies are small and have shown conflicting... [详情]

阳光明媚评论了文献：

05-16 09:33

Hypertensive diseases in pregnancy and breast cancer risk.

Background:Hypertensive diseases in pregnancy may be associated with a reduced risk of breast cancer. Most previous studies are small and have shown conflicting... [详情]

该研究纳入了一个由1967～2008年间919712例初产妇组成的队列，并与两个英国国家登记处的资料进行关联，进而评估了妊娠高血压女性的乳腺癌风险是否降低。结果显示，与妊娠期间血压正常的初产妇相比，有妊娠高血压或

阳光明媚收藏了文献：

05-16 09:32

Hypertensive diseases in pregnancy and breast cancer risk.

Background:Hypertensive diseases in pregnancy may be associated with a reduced risk of breast cancer. Most previous studies are small and have shown conflicting... [详情]

阳光明媚发表了话题：

05-11 14:05

【文献品评】综述：抗血管生成治疗进展

靶向VEGF或其受体的抗血管生成治疗已经成为多种恶性肿瘤治疗的主流。但是，这些药物的临床有效性比原先预期的要低，在多数情况下，需要添加细胞毒化疗。和其他靶向治疗一样...[详情]

阳光明媚评论了文献：

05-11 13:23

阿司匹林在癌症预防中的作用

Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin... [详情]

最近发表的心血管临床试验的二次分析提供了第一个随机证据表明，日服阿司匹林可以降低癌症整体的发病率，即使是低剂量（75~100mg/天）。

阳光明媚上传了文献全文：

05-11 13:12

The role of aspirin in cancer prevention.

阳光明媚翻译了文献标题：

05-11 10:39

厄洛替尼 vs 标准化疗一线治疗EGFR突变阳性晚期非小细胞肺癌的欧洲患者（EURTAC）：一项多...

BACKGROUND:Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with n... [详情]

阳光明媚评论了文献：

05-11 09:50

Erlotinib versus standard chemotherapy as first-line treatment for European patients ...

BACKGROUND:Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with n... [详情]

研究人员将174名非小细胞肺癌的欧洲患者随机分为两组，一组接受EGFR-TKI 厄洛替尼单药治疗，一组是以铂类为基础的联合化疗方案，化疗药物还包括多西他赛或吉西他滨。中期分析显示，厄洛替尼组的无进展生存期显著提高

阳光明媚收藏了文献：

05-11 09:48

Erlotinib versus standard chemotherapy as first-line treatment for European patients ...

BACKGROUND:Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with n... [详情]

阳光明媚翻译了文献标题：

05-10 16:48

舒尼替尼+厄洛替尼 vs 安慰剂+厄洛替尼用于先前接受过治疗的晚期非小细胞肺癌患者：一项III...

PURPOSESunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance o... [详情]

阳光明媚评论了文献：

05-10 15:16

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Tr...

PURPOSESunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance o... [详情]

《临床肿瘤学杂志》（Journal of Clinical Oncology）近期发表的一项研究表明，在难治性非小细胞肺癌（NSCLC）患者中，舒尼替尼+厄洛替尼联合用药较厄洛替尼单药治疗不能延长其总生存期（OS），但联合治疗与显著较

阳光明媚收藏了文献：

05-10 15:15

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Tr...

PURPOSESunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance o... [详情]

更多动态